Lonza shells out $107M cash to snap up Synaffix and its ADC platform

01 Jun 2023
endpts.com
ADCAcquisition
After lining up a string of partnerships over the years, Dutch antibody-drug conjugate specialist Synaffix has found a new home: Lonza, the contract development and manufacturing giant.
Lonza is paying about $107 million (€100 million) in cash to acquire SynaffixSynaffix, with up to $64 million (€60 million) in “additional performance-based consideration” on the table. Synaffix’s ADC tech platform will now become part of Lonza’s offering for biopharma clients, lending its bioconjugate technologies to not just ADCs but also targeted gene therapy, immune cell engagers and other applications.
Lonza shells out $107M cash to snap up Synaffix and its ADC platform
Preview
Source: EndPoints
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 170,400+ biopharma pros reading Endpoints daily — and it's free.
SIGN UP
LOG IN
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.